Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Role of Cytokines and Their Antagonists in the Treatment of Covid-19 Patients Publisher Pubmed



Mohseni Afshar Z1 ; Barary M2, 3 ; Babazadeh A4 ; Tavakoli Pirzaman A5 ; Hosseinzadeh R5 ; Alijanpour A6 ; Allahgholipour A7 ; Miri SR8 ; Sio TT9 ; Sullman MJM10, 11 ; Carsonchahhoud K12 ; Ebrahimpour S4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
  2. 2. Student Research Committee, Virtual School of Medical Education and Management, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Students' Scientific Research Center (SSRC), Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
  5. 5. Student Research Committee, Babol University of Medical Sciences, Babol, Iran
  6. 6. Faculty of Medicine, Semmelweis University, Budapest, Hungary
  7. 7. Student Research Committee, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  8. 8. Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Science, Tehran, Iran
  9. 9. Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, United States
  10. 10. Department of Social Sciences, University of Nicosia, Nicosia, Cyprus
  11. 11. Department of Life and Health Sciences, University of Nicosia, Nicosia, Cyprus
  12. 12. Australian Centre for Precision Health, University of South Australia, Adelaide, Australia

Source: Reviews in Medical Virology Published:2023


Abstract

The coronavirus disease 2019 (COVID-19) has various presentations, of which immune dysregulation or the so-called cytokine storm syndrome (COVID-CSS) is prominent. Even though cytokines are vital regulators of body immunoinflammatory responses, their exaggerated release can be harmful. This hyperinflammatory response is more commonly observed during severe COVID-19 infections, caused by the excessive release of pro-inflammatory cytokines, such as interleukin-1 (IL-1), IL-6, IL-8, tumour necrosis factor, granulocyte-macrophage colony-stimulating factor, and interferon-gamma, making their blockers and antagonists of great interest as therapeutic options in this condition. Thus, the pathophysiology of excessive cytokine secretion is outlined, and their most important blockers and antagonists are discussed, mainly focussing on tocilizumab, an interleukin-6 receptor blocker approved to treat severe COVID-19 infections. © 2022 John Wiley & Sons Ltd.
Other Related Docs
9. Anticoagulant Therapy in Covid-19: A Narrative Review, Clinical and Translational Science (2023)
17. Pharmacological Treatments of Covid-19, Pharmacological Reports (2020)
18. Immune-Based Therapeutic Approaches in Covid-19, Biomedicine and Pharmacotherapy (2022)
25. Covid-19 in Patients With Cancer: Risks and Precautions, American Journal of Emergency Medicine (2021)
45. Cancer Care Management During the Covid-19 Pandemic, Risk Management and Healthcare Policy (2020)
49. Sars-Cov-2 and Acute Cerebrovascular Events: An Overview, Journal of Clinical Medicine (2021)